GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (NAS:SGMT) » Definitions » Shares Outstanding (Diluted Average)

SGMT (Sagimet Biosciences) Shares Outstanding (Diluted Average) : 32.14 Mil (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sagimet Biosciences Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Sagimet Biosciences's average diluted shares outstanding for the quarter that ended in Sep. 2024 was 32.14 Mil.


Sagimet Biosciences Shares Outstanding (Diluted Average) Historical Data

The historical data trend for Sagimet Biosciences's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagimet Biosciences Shares Outstanding (Diluted Average) Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (Diluted Average)
22.17 22.17 22.17 22.17 10.46

Sagimet Biosciences Quarterly Data
Dec19 Mar20 Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Outstanding (Diluted Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.20 22.90 29.04 31.91 32.14

Sagimet Biosciences Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Sagimet Biosciences  (NAS:SGMT) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Sagimet Biosciences Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of Sagimet Biosciences's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Sagimet Biosciences Business Description

Industry
Traded in Other Exchanges
Address
155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
Executives
George Kemble director SAGIMET BIOSCIENCES INC., 155 BOVET RD., STE. 303, SAN MATEO CA 94402
Elizabeth Rozek officer: General Counsel and CCO SAGIMET BIOSCIENCES INC., 155 BOVET ROAD, SUITE 303, SAN MATEO CA 94402
Eduardo Bruno Martins director 350 CAMBRIDGE AVE, SUITE 350, PALO ALTO CA 94306
David Happel director, officer: President & CEO 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Beth C Seidenberg director
Nea 13 Gp, Ltd 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Jinzi Jason Wu director SAGIMET BIOSCIENCES INC., 155 BOVET RD., SUITE 303, SAN MATEO CA 94402
Dennis Hom officer: Chief Financial Officer C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Kpcb Pbd Associates, Llc 10 percent owner C/O KLEINER PERKINS CAUFIELD & BYERS, 2750 SAND HILL ROAD, MENLO PARK CA 94025
Kpcb Pandemic & Bio Defense Fund Llc 10 percent owner 2750 SAND HILL RD, MENLO PARK CA 94025
Nea Partners 13, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Elizabeth A Grammer director 78TH FOURTH AVENUE, WALTHAM MA 02451
Anthony M Rimac officer: Chief Operating Officer C/O ADAMAS PHARMACEUTICALS, INC., 2200 POWELL ST, STE 220, EMERYVILLE CA 94608
Patrick J Kerins 10 percent owner

Sagimet Biosciences Headlines

From GuruFocus